HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Relugolix (Primary) ; Leuprorelin
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms HERO
- Sponsors Myovant Sciences
- 27 Feb 2018 Planned number of patients changed from 1125 to 915.
- 01 Mar 2017 Status changed from planning to recruiting.
- 27 Oct 2016 New trial record